Pivotal bioVenture Partners Fund I U.G.P. Ltd does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Inozyme Pharma, Inc., Entasis Therapeutics Holdings Inc., and Evommune, Inc..

2018 was Pivotal bioVenture Partners Fund I U.G.P. Ltd's most active year for acquiring shares with 3 total transactions. Pivotal bioVenture Partners Fund I U.G.P. Ltd's most active month to acquire stocks was the month of August. 2025 was Pivotal bioVenture Partners Fund I U.G.P. Ltd's most active year for disposing of shares, totalling 9 transactions. Pivotal bioVenture Partners Fund I U.G.P. Ltd's most active month to dispose stocks was the month of October. 2018 saw Pivotal bioVenture Partners Fund I U.G.P. Ltd paying a total of $5,065,860.00 for 1,155,416 shares, this is the most they've acquired in one year. In 2020 Pivotal bioVenture Partners Fund I U.G.P. Ltd cashed out on 10,489,510 shares for a total of $0.00, their largest year based on trade value.